# US 11,433,073 B2 · Compositions and methods for the prevention and treatment of hearing loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,433,073 B2
- Document ID: US11433073B2
- Status: Granted
- Kind: B2
- Application number: 17/580,755
- Filed: 2022-01-21
- Published: 2022-05-05
- Granted: 2022-09-06
- Earliest claimed: 2019-12-12
- Assignees: Ting Therapeutics LLC
- Applicants: Ting Therapeutics LLC
- Inventors: Jian Zuo; Tai Teitz
- Web page: https://patentgrep.com/patent/US11433073B2

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 27/16: Otologicals
- C07K 14/71: for growth factors; for growth regulators
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.

## Claims

### Claim 1

A method to prevent cisplatin-induced hearing loss comprising: orally administering to animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib to prevent hearing loss due to cisplatin treatment, wherein the sufficient amount of Dabrafenib is 100 mg/kg.

### Claim 2 (depends on 1)

The method of claim 1, comprising: orally co-administering to animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib and Trametinib to prevent hearing loss due to cisplatin treatment, wherein the sufficient amount of Trametinib is 2 mg/kg twice daily.

### Claim 3

A method to prevent noise induced hearing loss comprising: orally administering to an animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib to prevent hearing loss due to a noise exposure, wherein the sufficient amount of Dabrafenib is 100 mg/kg twice daily.

### Claim 4 (depends on 3)

The method of claim 3, wherein Dabrafenib is administered 45 minutes before the noise exposure.

### Claim 5 (depends on 3)

The method of claim 3, wherein Dabrafenib is administered for three days after the noise exposure.

### Claim 6 (depends on 3)

The method of claim 3, comprising co-administering a pharmaceutical composition comprised of: a sufficient amount of AZD5438 to prevent hearing loss due to a noise exposure.

### Claim 7 (depends on 3)

The method of claim 3, wherein Dabrafenib is administered 45 minutes before the noise exposure, wherein the sufficient amount of Dabrafenib is 60 mg/kg twice daily.

### Claim 8

A method to prevent noise induced hearing loss comprising: orally administering to an animal in need thereof a pharmaceutical composition comprised of: a sufficient amount of Dabrafenib to prevent hearing loss due to a noise exposure wherein the sufficient amount of Dabrafenib is 60 mg/kg twice daily and administering a sufficient amount of AZD5438.

### Claim 9 (depends on 8)

The method of claim 8, wherein the sufficient amount of AZD5438 is 35 mg/kg twice daily.